Article

Low Pain Thresholds in RA Reflect “Fibromyalgic” Disease

In patients with rheumatoid arthritis (RA), low pain thresholds reflect "fibromyalgic" RA (many tender points) and central pain sensitization with a prolonged disease duration.

In patients with rheumatoid arthritis (RA), low pain thresholds reflect "fibromyalgic" RA (many tender points) and central pain sensitization with a prolonged disease duration. Early and intensive treatment that minimizes inflammation is likely to reduce central sensitization and minimize long-term RA pain; biologic therapies may play a crucial role.

Pollard and coworkers conducted a cross-sectional observational study of 105 outpatients with RA. To assess pain thresholds, they used the mean of 2 measurements made by a single assessor using a handheld digital algometer applied to the thumbnail. They recorded demographic data, physician global assessment, early morning stiffness, and 28-joint count Disease Activity Score (DAS 28) and its constituents. Fibromyalgic tender point assessment used methods recommended for diagnosis of fibromyalgia syndrome. Pain, fatigue, disability, and mental health were measured.

The median pain threshold was 289 kPa (interquartile range, 89 to 434 kPa). Pain thresholds showed high correlations with tender point counts, tender joint counts, fatigue, DAS 28, and disability. Moderate correlations included pain, depression and anxiety scores, and patient global assessment.

The authors suggested that over time, the burden of inflammation in RA may lead to persistence of pain as well as cause progressive joint damage and functional decline.

Related Videos
Orrin Troum, MD: Accurately Imaging Gout With DECT Scanning
John Stone, MD, MPH: Continuing Progress With IgG4-Related Disease Research
Philip Conaghan, MBBS, PhD: Investigating NT3 Inhibition for Improving Osteoarthritis
Rheumatologists Recognize the Need to Create Pediatric Enthesitis Scoring Tool
Presence of Diffuse Cutaneous Disease Linked to Worse HRQOL in Systematic Sclerosis
Alexei Grom, MD: Exploring Safer Treatment Options for Refractory Macrophage Activation Syndrome
Jack Arnold, MBBS, clinical research fellow, University of Leeds, Leeds Institute of Rheumatic and Musculoskeletal Medicine
John Tesser, MD, Adjunct Assistant Professor of Medicine, Midwestern University, and Arizona College of Osteopathic Medicine, and Lecturer, University of Arizona Health Sciences Center, and Arizona Arthritis & Rheumatology Associates
Gaith Noaiseh, MD: Nipocalimab Improves Disease Measures, Reduces Autoantibodies in Sjogren’s
Laure Gossec, MD, PhD: Informing Physician Treatment Choices for Psoriatic Arthritis
© 2024 MJH Life Sciences

All rights reserved.